The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Pediatric Influenza Treatment Market Research Report 2025
Synopsis
Most kids are enrolled in early education and child care programs. Seasonal influenza outbreaks are expected annually. Influenza can be severe, resulting in hospitalization or death of some children. Immunization against influenza is the best strategy to reduce infection and spread.
The global Pediatric Influenza Treatment market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Pediatric Influenza Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Pediatric Influenza Treatment.
Report Scope
The Pediatric Influenza Treatment market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Pediatric Influenza Treatment market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Pediatric Influenza Treatment companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
F. Hoffmann-La Roche Ltd
GlaxoSmithKline Plc.
NATCO Pharma Limited.
NESHER PHARMS
Johnson & Johnsons Inc.
Cipla
Hetero Pharma
Teva Pharmaceutical pvt. Ltd.
Olainfarm JSC
Gilead Sciences, Inc.
Segment by Type
Antiviral Drug
Antipyretic
Neuraminidase inhibitor
Others
Segment by Application
Hospitals
Clinics
Ambulatory Surgical Centers
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Pediatric Influenza Treatment companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Most kids are enrolled in early education and child care programs. Seasonal influenza outbreaks are expected annually. Influenza can be severe, resulting in hospitalization or death of some children. Immunization against influenza is the best strategy to reduce infection and spread.
The global Pediatric Influenza Treatment market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Pediatric Influenza Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Pediatric Influenza Treatment.
Report Scope
The Pediatric Influenza Treatment market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Pediatric Influenza Treatment market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Pediatric Influenza Treatment companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
F. Hoffmann-La Roche Ltd
GlaxoSmithKline Plc.
NATCO Pharma Limited.
NESHER PHARMS
Johnson & Johnsons Inc.
Cipla
Hetero Pharma
Teva Pharmaceutical pvt. Ltd.
Olainfarm JSC
Gilead Sciences, Inc.
Segment by Type
Antiviral Drug
Antipyretic
Neuraminidase inhibitor
Others
Segment by Application
Hospitals
Clinics
Ambulatory Surgical Centers
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Pediatric Influenza Treatment companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Pediatric Influenza Treatment Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Antiviral Drug
1.2.3 Antipyretic
1.2.4 Neuraminidase inhibitor
1.2.5 Others
1.3 Market by Application
1.3.1 Global Pediatric Influenza Treatment Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Ambulatory Surgical Centers
1.3.5 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Pediatric Influenza Treatment Market Perspective (2019-2030)
2.2 Pediatric Influenza Treatment Growth Trends by Region
2.2.1 Global Pediatric Influenza Treatment Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Pediatric Influenza Treatment Historic Market Size by Region (2019-2024)
2.2.3 Pediatric Influenza Treatment Forecasted Market Size by Region (2025-2030)
2.3 Pediatric Influenza Treatment Market Dynamics
2.3.1 Pediatric Influenza Treatment Industry Trends
2.3.2 Pediatric Influenza Treatment Market Drivers
2.3.3 Pediatric Influenza Treatment Market Challenges
2.3.4 Pediatric Influenza Treatment Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Pediatric Influenza Treatment Players by Revenue
3.1.1 Global Top Pediatric Influenza Treatment Players by Revenue (2019-2024)
3.1.2 Global Pediatric Influenza Treatment Revenue Market Share by Players (2019-2024)
3.2 Global Pediatric Influenza Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Pediatric Influenza Treatment Revenue
3.4 Global Pediatric Influenza Treatment Market Concentration Ratio
3.4.1 Global Pediatric Influenza Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Pediatric Influenza Treatment Revenue in 2023
3.5 Pediatric Influenza Treatment Key Players Head office and Area Served
3.6 Key Players Pediatric Influenza Treatment Product Solution and Service
3.7 Date of Enter into Pediatric Influenza Treatment Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Pediatric Influenza Treatment Breakdown Data by Type
4.1 Global Pediatric Influenza Treatment Historic Market Size by Type (2019-2024)
4.2 Global Pediatric Influenza Treatment Forecasted Market Size by Type (2025-2030)
5 Pediatric Influenza Treatment Breakdown Data by Application
5.1 Global Pediatric Influenza Treatment Historic Market Size by Application (2019-2024)
5.2 Global Pediatric Influenza Treatment Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Pediatric Influenza Treatment Market Size (2019-2030)
6.2 North America Pediatric Influenza Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Pediatric Influenza Treatment Market Size by Country (2019-2024)
6.4 North America Pediatric Influenza Treatment Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Pediatric Influenza Treatment Market Size (2019-2030)
7.2 Europe Pediatric Influenza Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Pediatric Influenza Treatment Market Size by Country (2019-2024)
7.4 Europe Pediatric Influenza Treatment Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Pediatric Influenza Treatment Market Size (2019-2030)
8.2 Asia-Pacific Pediatric Influenza Treatment Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Pediatric Influenza Treatment Market Size by Region (2019-2024)
8.4 Asia-Pacific Pediatric Influenza Treatment Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Pediatric Influenza Treatment Market Size (2019-2030)
9.2 Latin America Pediatric Influenza Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Pediatric Influenza Treatment Market Size by Country (2019-2024)
9.4 Latin America Pediatric Influenza Treatment Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Pediatric Influenza Treatment Market Size (2019-2030)
10.2 Middle East & Africa Pediatric Influenza Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Pediatric Influenza Treatment Market Size by Country (2019-2024)
10.4 Middle East & Africa Pediatric Influenza Treatment Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 F. Hoffmann-La Roche Ltd
11.1.1 F. Hoffmann-La Roche Ltd Company Detail
11.1.2 F. Hoffmann-La Roche Ltd Business Overview
11.1.3 F. Hoffmann-La Roche Ltd Pediatric Influenza Treatment Introduction
11.1.4 F. Hoffmann-La Roche Ltd Revenue in Pediatric Influenza Treatment Business (2019-2024)
11.1.5 F. Hoffmann-La Roche Ltd Recent Development
11.2 GlaxoSmithKline Plc.
11.2.1 GlaxoSmithKline Plc. Company Detail
11.2.2 GlaxoSmithKline Plc. Business Overview
11.2.3 GlaxoSmithKline Plc. Pediatric Influenza Treatment Introduction
11.2.4 GlaxoSmithKline Plc. Revenue in Pediatric Influenza Treatment Business (2019-2024)
11.2.5 GlaxoSmithKline Plc. Recent Development
11.3 NATCO Pharma Limited.
11.3.1 NATCO Pharma Limited. Company Detail
11.3.2 NATCO Pharma Limited. Business Overview
11.3.3 NATCO Pharma Limited. Pediatric Influenza Treatment Introduction
11.3.4 NATCO Pharma Limited. Revenue in Pediatric Influenza Treatment Business (2019-2024)
11.3.5 NATCO Pharma Limited. Recent Development
11.4 NESHER PHARMS
11.4.1 NESHER PHARMS Company Detail
11.4.2 NESHER PHARMS Business Overview
11.4.3 NESHER PHARMS Pediatric Influenza Treatment Introduction
11.4.4 NESHER PHARMS Revenue in Pediatric Influenza Treatment Business (2019-2024)
11.4.5 NESHER PHARMS Recent Development
11.5 Johnson & Johnsons Inc.
11.5.1 Johnson & Johnsons Inc. Company Detail
11.5.2 Johnson & Johnsons Inc. Business Overview
11.5.3 Johnson & Johnsons Inc. Pediatric Influenza Treatment Introduction
11.5.4 Johnson & Johnsons Inc. Revenue in Pediatric Influenza Treatment Business (2019-2024)
11.5.5 Johnson & Johnsons Inc. Recent Development
11.6 Cipla
11.6.1 Cipla Company Detail
11.6.2 Cipla Business Overview
11.6.3 Cipla Pediatric Influenza Treatment Introduction
11.6.4 Cipla Revenue in Pediatric Influenza Treatment Business (2019-2024)
11.6.5 Cipla Recent Development
11.7 Hetero Pharma
11.7.1 Hetero Pharma Company Detail
11.7.2 Hetero Pharma Business Overview
11.7.3 Hetero Pharma Pediatric Influenza Treatment Introduction
11.7.4 Hetero Pharma Revenue in Pediatric Influenza Treatment Business (2019-2024)
11.7.5 Hetero Pharma Recent Development
11.8 Teva Pharmaceutical pvt. Ltd.
11.8.1 Teva Pharmaceutical pvt. Ltd. Company Detail
11.8.2 Teva Pharmaceutical pvt. Ltd. Business Overview
11.8.3 Teva Pharmaceutical pvt. Ltd. Pediatric Influenza Treatment Introduction
11.8.4 Teva Pharmaceutical pvt. Ltd. Revenue in Pediatric Influenza Treatment Business (2019-2024)
11.8.5 Teva Pharmaceutical pvt. Ltd. Recent Development
11.9 Olainfarm JSC
11.9.1 Olainfarm JSC Company Detail
11.9.2 Olainfarm JSC Business Overview
11.9.3 Olainfarm JSC Pediatric Influenza Treatment Introduction
11.9.4 Olainfarm JSC Revenue in Pediatric Influenza Treatment Business (2019-2024)
11.9.5 Olainfarm JSC Recent Development
11.10 Gilead Sciences, Inc.
11.10.1 Gilead Sciences, Inc. Company Detail
11.10.2 Gilead Sciences, Inc. Business Overview
11.10.3 Gilead Sciences, Inc. Pediatric Influenza Treatment Introduction
11.10.4 Gilead Sciences, Inc. Revenue in Pediatric Influenza Treatment Business (2019-2024)
11.10.5 Gilead Sciences, Inc. Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
